Table 4.
Summary statistics for factor XI clotting activity (FXI:C), stratified by BMS‐962212 dose panel, immediately prior to the end of infusion in part A and part B for non‐Japanese and Japanese subjects
| Dose (mg h−1) | N | Mean Observed FXI:C (± SEM) (%) | % Change from baseline |
|---|---|---|---|
| Part A (2‐h IV infusion) | |||
| Placebo | 8 | 99 ± 4.4 | −2.3 |
| 1.5 | 6 | 80.3 ± 4.1 | −20 |
| 4 | 6 | 49.0 ± 2.8 | −46 |
| 10 | 6 | 28.2 ± 2.9 | −73 |
| 25 | 6 | 15.5 ± 6.0 | −83 |
| Part B (5‐day IV infusion) (non‐Japanese subjects) | |||
| Placebo | 4 | 102 ± 3.6 | 0 |
| 1 | 4 | 70.3 ± 6.3 | −25 |
| 3 | 4 | 59.8 ± 5.3 | −40 |
| 9 | 4 | 26 ± 3.0 | −74 |
| 20 | 4 | 14 ± 3.5 | −85 |
| Part B (5‐day IV infusion) (Japanese subjects) | |||
| Placebo | 4 | 100.2 ± 8.2 | +1 |
| 1 | 4 | 78.8 ± 2.8 | −16 |
| 3 | 4 | 60.0 ± 7.2 | −42 |
| 9 | 4 | 30.8 ± 4.1 | −70 |
| 20 | 4 | 9.5 ± 1.2 | −90 |
IV, intravenous; SEM, standard error of the mean